<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296360</url>
  </required_header>
  <id_info>
    <org_study_id>IC51-325</org_study_id>
    <nct_id>NCT01296360</nct_id>
  </id_info>
  <brief_title>Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country</brief_title>
  <official_title>Long-Term Immunity and Safety With or Without a Booster Dose Following Primary Vaccination With the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population in a JEV-Endemic Country. Open-Label, Randomized, Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label Phase 3 study including children aged &gt;9 months to &lt;17 years
      and 7 months who have been vaccinated with IXIARO in study IC51-323.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label Phase 3 study including children aged &gt;9 months to &lt;17 years
      and 7 months who have been vaccinated with IXIARO in the previous study IC51-323.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SCRs (Seroconversion Rate) as Defined by Percentage of Subjects With Plaque Reduction Neutralization Test Titers of&gt;1:10 at 1 Month After the Booster Dose</measure>
    <time_frame>1 month post booster</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects Achieving a &gt;4-fold Increase in JEV (Japanese Encephalitis Virus) Neutralizing Antibody Titers at 1 Month After the Booster Dose</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs (Geometric Mean Titre) for JEV Neutralizing Antibodies Measured Using a Validated PRNT (Plaque Reduction Neutralization Test) at 1 Month After the Booster Dose</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs and Rate of Subjects With a PRNT Titer of &gt;1:10 at Months 12, 24 and 36 After First IXIARO Vaccination in IC51-323 With and Without Booster Vaccination</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With SAEs (Serious Adverse Events) Following Immunization and Medically Attended AEs (Adverse Events) up to Months 12, 24 and 36 After the First IXIARO Vaccination in IC51 323 With and Without Booster Vaccination. Severity, Duration and</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With Unsolicited AEs (Adverse Events) up to Months 12, 24 and 36 After the First IXIARO Vaccination in IC51 323 With and Without Booster Vaccination. Severity, Duration and Relationship to Vaccinations.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With SAEs and Medically Attended AEs Within 1 Month Following the Booster Dose. Severity, Duration and Relationship to Vaccinations.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With Unsolicited AEs Within 1 Month Following the Booster Dose. Severity, Duration and Relationship to Vaccinations.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With Solicited AEs for up to 7 Days Following the Booster Dose. Severity and Duration.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>&gt;14 months to &lt;2 years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IXIARO 0.25 ml i.m. (milliliter, intramuscular)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&gt;3 years - &lt;18 years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IXIARO 0.5 ml i.m (milliliter, intramuscular)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IXIARO</intervention_name>
    <description>0.25 ml i.m. (milliliter, intramuscular)</description>
    <arm_group_label>&gt;14 months to &lt;2 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IXIARO</intervention_name>
    <description>0.5 ml i.m. (milliliter, intramuscular)</description>
    <arm_group_label>&gt;3 years - &lt;18 years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children and adolescents who have completed study IC51-323 and received both IXIARO
             vaccinations according to protocol.

          -  Children who have received the dose confirmed for their age group.

          -  Male or female healthy children and adolescents aged ≥9 months to &lt;17 years and 7
             months at the time of enrolment into this study.

          -  Written informed consent by the subject's legal representative(s), according to local
             requirements, and written informed assent of the subject, if applicable.

          -  Female subjects: either no childbearing potential or negative pregnancy test
             (pregnancy test to be performed in female subjects after onset of menarche) at Visits
             1, 2 and 2a as stipulated by the protocol. For females after menarche willingness to
             practice a reliable method of contraception

        Exclusion Criteria:

          -  Vaccination against JE virus (JEV) (except within study IC51-323 and IC51 325), Yellow
             fever, West Nile virus and Dengue fever at any time prior to or planned during the
             study.

          -  History of or clinical manifestation of any Flavivirus disease during IC51-323 or IC51
             325.

          -  Participation in another study with an investigational drug during IC51 323 or IC51
             325.

          -  Planned active or passive immunization within 2 weeks before and 1 week after the
             IXIARO booster.

          -  History of or development of any immunodeficiency including post-organ-transplantation
             after inclusion into IC51-323 or IC51 325.

          -  History of or development of an autoimmune disease during study IC51-323 or IC51 325.

               -  Administration of chronic (defined as more than 14 days) immunosuppressants or
                  other immune-modifying medications started during IC51-323 or IC51 325. (For
                  corticosteroids, this would mean prednisone or equivalent at &gt;0.05 mg/kg/day;
                  topical and inhaled steroids are allowed).

          -  Acute febrile infection at Visit 2 (only for the Booster Group).

          -  Pregnancy (positive pregnancy test at Visit 1 and Visit 2), lactation or unreliable
             contraception in female subjects after onset of menarche.

          -  Hypersensitivity reactions to IXIARO or adverse events in study IC51-323 requiring
             withdrawal from further vaccination or anaphylaxis or severe cases of atopy requiring
             emergency treatment or hospital admission during IC51-323 or IC51 325.

          -  History of urticaria after hymenoptera envenomation, drugs, physical or other
             provocations or of idiopathic cause during IC51-323 or IC51 325.

          -  Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV)
             (measurement of Hepatitis B surface antigen [HBsAg] titers) or hepatitis C virus
             (HCV).

          -  Illicit drug use and/or current drug or alcohol addiction.

          -  Inability or unwillingness by the legal representative(s) and/or the subject (where
             applicable) to provide informed consent/assent and to abide by the requirements of the
             study.

          -  Persons who have been committed to an institution (by a court or by an authority).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vera Kadlecek, Mag.</last_name>
    <role>Study Chair</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine - Clinical Research Division</name>
      <address>
        <city>Muntinlupa City</city>
        <state>Alabang</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine</name>
      <address>
        <city>Muntinlupa City</city>
        <state>Alabang</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UP-Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2010</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <results_first_submitted>December 10, 2014</results_first_submitted>
  <results_first_submitted_qc>December 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2014</results_first_posted>
  <last_update_submitted>December 10, 2014</last_update_submitted>
  <last_update_submitted_qc>December 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immune response</keyword>
  <keyword>IC51-325</keyword>
  <keyword>Japanese Encephalitis</keyword>
  <keyword>Intercell AG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Booster Group</title>
          <description>IC51 booster vaccination ~12 months after primary immunization in study IC51-323</description>
        </group>
        <group group_id="P2">
          <title>Non-Booster Group</title>
          <description>No treatment in study IC51-325</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 2 (Month 12)</title>
              <participants_list>
                <participants group_id="P1" count="148">booster was administered</participants>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 2a (Month 13)</title>
              <participants_list>
                <participants group_id="P1" count="148">visit in Booster Group only: ~13 months after immunization in IC51-323 (i.e., 1 month post booster)</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population: subjects who entered into the study and were randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Booster Group</title>
          <description>IC51 booster vaccination ~12 months after primary immunization in study IC51-323</description>
        </group>
        <group group_id="B2">
          <title>Non-Booster Group</title>
          <description>No treatment in study IC51-325</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.23" spread="5.084"/>
                    <measurement group_id="B2" value="5.36" spread="5.135"/>
                    <measurement group_id="B3" value="5.30" spread="5.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SCRs (Seroconversion Rate) as Defined by Percentage of Subjects With Plaque Reduction Neutralization Test Titers of&gt;1:10 at 1 Month After the Booster Dose</title>
        <time_frame>1 month post booster</time_frame>
        <population>Intent-to-treat Population: primary analysis population for the immunogenicity analyses; defined as all subjects randomized</population>
        <group_list>
          <group group_id="O1">
            <title>&gt;14 Months to &lt;2 Years</title>
            <description>booster vaccination: IXIARO 0.25 ml i.m. (milliliter, intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>&gt;3 Years - &lt;18 Years</title>
            <description>booster vaccination: IXIARO 0.5 ml i.m (milliliter, intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>SCRs (Seroconversion Rate) as Defined by Percentage of Subjects With Plaque Reduction Neutralization Test Titers of&gt;1:10 at 1 Month After the Booster Dose</title>
          <population>Intent-to-treat Population: primary analysis population for the immunogenicity analyses; defined as all subjects randomized</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95.5" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="94.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects Achieving a &gt;4-fold Increase in JEV (Japanese Encephalitis Virus) Neutralizing Antibody Titers at 1 Month After the Booster Dose</title>
        <time_frame>1 month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs (Geometric Mean Titre) for JEV Neutralizing Antibodies Measured Using a Validated PRNT (Plaque Reduction Neutralization Test) at 1 Month After the Booster Dose</title>
        <time_frame>1 month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs and Rate of Subjects With a PRNT Titer of &gt;1:10 at Months 12, 24 and 36 After First IXIARO Vaccination in IC51-323 With and Without Booster Vaccination</title>
        <time_frame>36 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With SAEs (Serious Adverse Events) Following Immunization and Medically Attended AEs (Adverse Events) up to Months 12, 24 and 36 After the First IXIARO Vaccination in IC51 323 With and Without Booster Vaccination. Severity, Duration and</title>
        <time_frame>36 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With Unsolicited AEs (Adverse Events) up to Months 12, 24 and 36 After the First IXIARO Vaccination in IC51 323 With and Without Booster Vaccination. Severity, Duration and Relationship to Vaccinations.</title>
        <time_frame>36 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With SAEs and Medically Attended AEs Within 1 Month Following the Booster Dose. Severity, Duration and Relationship to Vaccinations.</title>
        <time_frame>1 month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With Unsolicited AEs Within 1 Month Following the Booster Dose. Severity, Duration and Relationship to Vaccinations.</title>
        <time_frame>1 month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With Solicited AEs for up to 7 Days Following the Booster Dose. Severity and Duration.</title>
        <time_frame>7 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Booster Group</title>
          <description>IC51 booster vaccination ~12 months after primary immunization in study IC51-323</description>
        </group>
        <group group_id="E2">
          <title>Non-Booster Group</title>
          <description>No treatment in study IC51-325</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Finger amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>predefined term in subject diary; diary to be completed only by subjects receiving booster vaccination for 7 consecutive days</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Manager Clinical Research</name_or_title>
      <organization>Valneva Austria GmbH</organization>
      <phone>+43 1 206 20 ext 1175</phone>
      <email>katrin.dubischar-kastner@valneva.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

